慢性阻塞性肺疾病與毒蕈堿型膽堿能受體_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

張雨寒 ¹ ,  羅鳳鳴 ²

1. ;
2. ;

Corresponding?author：

羅鳳鳴, Email: luofengming@hotmail.com

Keywords：

DOI：

10.7507/1671-6205.201812005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 張雨寒, 羅鳳鳴. 慢性阻塞性肺疾病與毒蕈堿型膽堿能受體. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(9): 673-676. doi: 10.7507/1671-6205.201812005 Copy

1.	童朝暉. 中國老年慢性阻塞性肺疾病臨床診治實踐指南. 中華結核和呼吸雜志, 2020, 43(2): 100-119.
2.	申永春, 陳磊, 文富強. 2019 年慢性阻塞性肺疾病全球創議更新要點. 中華醫學雜志, 2018, 98(48): 3913-3916.
3.	Wang C, Xu J, Yang L, et al. China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study):a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
4.	Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther, 2005, 27(4): 377-392.
5.	胥曉麗, 徐天嬌. 心臟迷走神經-乙酰膽堿-M 受體研究概況. 現代醫藥衛生, 2013, 29(6): 868-869.
6.	Yao WZ, Wang GY, Zhu H, et al. Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease. Chin Med J (Eng), 2001, 114(1): 80-83.
7.	Hu J, Thor D, Zhou Y, et al. Structural aspects of M? muscarinic acetylcholine receptor dimer formation and activation. FASEB J, 2012, 26(2): 604-616.
8.	Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther, 2003, 98(1): 59-69.
9.	賴乾, 張毅, 李金田, 等. 毒蕈堿樣膽堿能受體在慢性阻塞性肺疾病中的作用. 中國老年學雜志, 2017, 37(24): 6256-6258.
10.	李新, 宋波. M 受體的研究進展. 國外醫學(藥學分冊), 2001, 28(1): 26-28.
11.	王昊, 郭政東, 李智. 毒蕈堿樣乙酰膽堿受體及其信號轉導. 生理科學進展, 2002, 33(3): 230-234.
12.	lkeda T, Anisuzzaman AS, Yoshiki H, et al. Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways. Br J Pharmacol, 2012, 166(6): 1804-1814.
13.	姚婉貞, 王國揚. 慢性阻塞性肺疾病的氣道毒蕈堿 M 受體變化與抗膽堿治療的研究. 中華結核和呼吸雜志, 2005, 28(7): 484-485.
14.	黃曉芬, 李金田, 張毅, 等. 毒蕈堿樣膽堿能受體在慢性阻塞性肺疾病防治中的研究進展. 中國呼吸與危重監護雜志, 2016, 15(1): 95-98.
15.	Kistemaker LE, Bos ST, Mudde WM, et al. Muscarinic M? receptors contribute to allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol, 2014, 50(4): 690-698.
16.	黃玉琦. 紋狀體 MSNs 中 M4 受體對 cAMP/DARPP-32 磷酸化信號通路的調控作用研究[D]. 寧夏: 寧夏醫科大學, 2016.
17.	杜威, 郭英, 袁維秀. 毒蕈堿乙酰膽堿 M2/M4 受體亞型在調節脊髓背角神經元谷氨酸能遞質釋放中的作用. 南方醫科大學學報, 2013, 33(6): 838-841.
18.	王麗韞, 鄭建全, 阮金秀, 等. 毒蕈堿型 M5 受體亞型及生物學特性. 中國藥理學通報, 2005, 21(1): 10-13.
19.	沈寧. COPD 患者氣道、肺組織膽堿能 M 受體及亞型的變化[D]. 北京: 北京大學, 2001.
20.	Yamada M, Ichinose M. The cholinergic anti-inflammatory pathway: an innovative treatment strategy for respiratory diseases and their comorbidities. Curr Opin Pharmacol, 2018, 40: 18-25.
21.	Koarai A, Ichinose M. Possible involvement of acetylcholine-mediated inflammation in airway diseases. Allergol Int, 2018, 67(4): 460-466.
22.	Gamo S, Tamada T, Murakami K, et al. TLR7 agonist attenuates acetylcholine-induced, Ca²⁺ -dependent ionic currents in swine tracheal submucosal gland cells. Exp Physiol, 2018, 103(11): 1543-1559.
23.	Montalbano AM, Di Sano C, Chiappara G, et al. Cigarette smoke and non-neuronal cholinergic system in the airway epithelium of COPD patients. J Cell Physiol, 2018, 233(8): 5856-5868.
24.	Kistemaker LE, Gosens R. Acetylcholine beyond bronehoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci, 2015, 36(3): 164-171.
25.	王藝曈, 王茜, 方翼. 新型抗膽堿藥物在慢性阻塞性肺疾病治療中的研究狀況. 中國臨床藥理學雜志, 2016, 32(10): 949-951,960.
26.	Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect, 2018, 6(3): e00400.
27.	Li X, Obeidat M, Zhou G, et al. Responsiveness to ipratropium bromide in male and female patients with mild to moderate chronic obstructive pulmonary disease. EBioMedicine, 2017, 19: 139-145.
28.	王智鵬. M3 受體拮抗劑的合成、活性及選擇性和 QSAR 及 QSSR[D]. 上海: 上海交通大學, 2014.
29.	Rodrigo GJ, Price DB, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis, 2017, 12: 907-922.
30.	Hizawa N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1093-1102.
31.	Barrecheguren M, Monteagudo M, Miravitlles M. Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care. NPJ Prim Care Respir Med, 2018, 28(1): 36.
32.	劉俊香, 王洪剛, 朱咪咪, 等. LAMA 和 LABA/ICS 聯合對 COPD 合并肺動脈高壓穩定期的療效. 牡丹江醫學院學報, 2017, 38(4): 24-27.
33.	Lane DC, Stemkowski S, Stanford RH, Tao Z. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U. S. Retrospective Database Study. J Manag Care Spec Pharm, 2018, 24(11): 1165-1172.
34.	Slebos DJ, Klooster K, Koegelenberg CFN, et al. Original article: Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax, 2015, 70(5): 411-419.
35.	Hummel JP, Mayse ML, Dimmer S, et al. Physiologic and histopathologic effects of targeted lung denervation in an animal model. J Appl Physiol (1985), 2019, 126(1): 67-76.
36.	Mineshita M, Inoue T, Miyazawa T. [Bronchoscopic treatments for COPD]. Nihon Rinsho, 2016, 74(5): 807-812.
37.	Valipour A, Asadi S, Pison C, et al. Long-term safety of bilateral targeted lung denervation in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2163-2172.

1. 童朝暉. 中國老年慢性阻塞性肺疾病臨床診治實踐指南. 中華結核和呼吸雜志, 2020, 43(2): 100-119.
2. 申永春, 陳磊, 文富強. 2019 年慢性阻塞性肺疾病全球創議更新要點. 中華醫學雜志, 2018, 98(48): 3913-3916.
3. Wang C, Xu J, Yang L, et al. China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study):a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
4. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther, 2005, 27(4): 377-392.
5. 胥曉麗, 徐天嬌. 心臟迷走神經-乙酰膽堿-M 受體研究概況. 現代醫藥衛生, 2013, 29(6): 868-869.
6. Yao WZ, Wang GY, Zhu H, et al. Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease. Chin Med J (Eng), 2001, 114(1): 80-83.
7. Hu J, Thor D, Zhou Y, et al. Structural aspects of M? muscarinic acetylcholine receptor dimer formation and activation. FASEB J, 2012, 26(2): 604-616.
8. Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther, 2003, 98(1): 59-69.
9. 賴乾, 張毅, 李金田, 等. 毒蕈堿樣膽堿能受體在慢性阻塞性肺疾病中的作用. 中國老年學雜志, 2017, 37(24): 6256-6258.
10. 李新, 宋波. M 受體的研究進展. 國外醫學(藥學分冊), 2001, 28(1): 26-28.
11. 王昊, 郭政東, 李智. 毒蕈堿樣乙酰膽堿受體及其信號轉導. 生理科學進展, 2002, 33(3): 230-234.
12. lkeda T, Anisuzzaman AS, Yoshiki H, et al. Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways. Br J Pharmacol, 2012, 166(6): 1804-1814.
13. 姚婉貞, 王國揚. 慢性阻塞性肺疾病的氣道毒蕈堿 M 受體變化與抗膽堿治療的研究. 中華結核和呼吸雜志, 2005, 28(7): 484-485.
14. 黃曉芬, 李金田, 張毅, 等. 毒蕈堿樣膽堿能受體在慢性阻塞性肺疾病防治中的研究進展. 中國呼吸與危重監護雜志, 2016, 15(1): 95-98.
15. Kistemaker LE, Bos ST, Mudde WM, et al. Muscarinic M? receptors contribute to allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol, 2014, 50(4): 690-698.
16. 黃玉琦. 紋狀體 MSNs 中 M4 受體對 cAMP/DARPP-32 磷酸化信號通路的調控作用研究[D]. 寧夏: 寧夏醫科大學, 2016.
17. 杜威, 郭英, 袁維秀. 毒蕈堿乙酰膽堿 M2/M4 受體亞型在調節脊髓背角神經元谷氨酸能遞質釋放中的作用. 南方醫科大學學報, 2013, 33(6): 838-841.
18. 王麗韞, 鄭建全, 阮金秀, 等. 毒蕈堿型 M5 受體亞型及生物學特性. 中國藥理學通報, 2005, 21(1): 10-13.
19. 沈寧. COPD 患者氣道、肺組織膽堿能 M 受體及亞型的變化[D]. 北京: 北京大學, 2001.
20. Yamada M, Ichinose M. The cholinergic anti-inflammatory pathway: an innovative treatment strategy for respiratory diseases and their comorbidities. Curr Opin Pharmacol, 2018, 40: 18-25.
21. Koarai A, Ichinose M. Possible involvement of acetylcholine-mediated inflammation in airway diseases. Allergol Int, 2018, 67(4): 460-466.
22. Gamo S, Tamada T, Murakami K, et al. TLR7 agonist attenuates acetylcholine-induced, Ca²⁺ -dependent ionic currents in swine tracheal submucosal gland cells. Exp Physiol, 2018, 103(11): 1543-1559.
23. Montalbano AM, Di Sano C, Chiappara G, et al. Cigarette smoke and non-neuronal cholinergic system in the airway epithelium of COPD patients. J Cell Physiol, 2018, 233(8): 5856-5868.
24. Kistemaker LE, Gosens R. Acetylcholine beyond bronehoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci, 2015, 36(3): 164-171.
25. 王藝曈, 王茜, 方翼. 新型抗膽堿藥物在慢性阻塞性肺疾病治療中的研究狀況. 中國臨床藥理學雜志, 2016, 32(10): 949-951,960.
26. Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect, 2018, 6(3): e00400.
27. Li X, Obeidat M, Zhou G, et al. Responsiveness to ipratropium bromide in male and female patients with mild to moderate chronic obstructive pulmonary disease. EBioMedicine, 2017, 19: 139-145.
28. 王智鵬. M3 受體拮抗劑的合成、活性及選擇性和 QSAR 及 QSSR[D]. 上海: 上海交通大學, 2014.
29. Rodrigo GJ, Price DB, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis, 2017, 12: 907-922.
30. Hizawa N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1093-1102.
31. Barrecheguren M, Monteagudo M, Miravitlles M. Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care. NPJ Prim Care Respir Med, 2018, 28(1): 36.
32. 劉俊香, 王洪剛, 朱咪咪, 等. LAMA 和 LABA/ICS 聯合對 COPD 合并肺動脈高壓穩定期的療效. 牡丹江醫學院學報, 2017, 38(4): 24-27.
33. Lane DC, Stemkowski S, Stanford RH, Tao Z. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U. S. Retrospective Database Study. J Manag Care Spec Pharm, 2018, 24(11): 1165-1172.
34. Slebos DJ, Klooster K, Koegelenberg CFN, et al. Original article: Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax, 2015, 70(5): 411-419.
35. Hummel JP, Mayse ML, Dimmer S, et al. Physiologic and histopathologic effects of targeted lung denervation in an animal model. J Appl Physiol (1985), 2019, 126(1): 67-76.
36. Mineshita M, Inoue T, Miyazawa T. [Bronchoscopic treatments for COPD]. Nihon Rinsho, 2016, 74(5): 807-812.
37. Valipour A, Asadi S, Pison C, et al. Long-term safety of bilateral targeted lung denervation in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2163-2172.

Previous Article
反復出現的肺部多發結節、空洞影
Next Article
影像引導經胸壁肺穿刺術診斷肺結節的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

慢性阻塞性肺疾病與毒蕈堿型膽堿能受體

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content